Risk of Infection in Lymphoma Patients Receiving Rituximab
Author Information
Author(s): Lanini Simone, Molloy Aoife C, Fine Paul E, Prentice Archibald G, Ippolito Giuseppe, Kibbler Christopher C
Primary Institution: National Institute for Infectious Diseases, INMI-Lazzaro Spallanzani
Hypothesis
Does the addition of Rituximab to chemotherapy increase the risk of severe infections in adults with CD20 positive malignant lymphomas?
Conclusion
Rituximab combined with chemotherapy does not increase the overall incidence of severe infections in lymphoma patients and improves treatment response.
Supporting Evidence
- The addition of Rituximab does not increase the overall risk of severe infections.
- Rituximab increases the risk of severe leucopenia and granulocytopenia.
- Patients receiving Rituximab have a better overall response to treatment.
Takeaway
This study found that adding a drug called Rituximab to chemotherapy for lymphoma patients doesn't make them more likely to get serious infections, and it helps them respond better to treatment.
Methodology
A systematic review and meta-analysis of randomized controlled trials comparing Rituximab plus chemotherapy to chemotherapy alone in adults with CD20 positive malignant lymphomas.
Potential Biases
All included studies were considered to be at high risk of bias due to lack of blinding and allocation concealment.
Limitations
The studies included were at high risk of bias, and data on specific patient groups like HIV positive individuals were lacking.
Participant Demographics
Participants were adults with CD20 positive malignant lymphomas, with a mean age between 50.0 and 69.2 years.
Statistical Information
P-Value
0.943 for infections, 0.279 for death from infection, <0.001 for leucopenia and overall response.
Confidence Interval
95% CI 0.87 to 1.14 for infections, 95% CI 0.68 to 3.75 for death from infection, 95% CI 1.12 to 1.37 for leucopenia, 95% CI 1.09 to 1.15 for overall response.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website